ClinicalTrials.gg
CompletedNCT00509028Updated Aug 27, 2012Results posted

Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma

A Phase 3 interventional study of Budesonide and Conventional Asthma Therapy in Asthma, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2012-08-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
241
Allocation
Non-randomized
Ages
5 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
39th of 108
241 · median 124
Started
2006
with 7 others
Phase 3
51 of 110
3 open now
Registered
28th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 39th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2006, is one of 51 in phase 3, and was the 28th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres. To investigate the safety of budesonide Turbuhaler® with a daily dose of 100 µg to 800 µg for 54 weeks treatment including the prior 6 weeks Phase III study (Study D5254C00769, NCT00504062) as compared with conventional therapy in Japanese children with bronchial asthma in need of inhaled glucocorticosteroid treatment.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Bronchial
04

Who can participate

Ages eligible
5 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who complete preceding the Phase III study and provide a signed written by patient's legal representative at Visit 1 or 4 weeks prior to Visit 1 of the study. A signed written informed assent should also be obtained from the patients themselves as much as possible
  • When the investigator will obtain the signed written informed consent of Phase III study (D5254C00769) from patient's legal representative, the investigator will also provide the information of this study

Exclusion criteria

Exclusion Criteria:

  • Respiratory infections that, in the opinion of the investigator(s), may affect the efficacy evaluation e.g., lower airways infection such as pneumonia, infection with no available effective antimicrobial drugs or with deep seated mycosis
  • Concurrent serious diseases of liver, kidney, heart or other complications which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study. Any abnormal findings in vital sign or physical examination at Visit 1 in this study, which in the opinion of the investigator may put the patient at risk because of his/her participation in the study.
  • Pregnant or possible pregnancy or planning to become pregnant during the study period
  • Other subjects who are considered inappropriate to participate in this study judged by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    BUD - Budesonide

    Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily

    Drug: Budesonide

  • Active comparator
    CONV - Conventional Asthma Therapy

    Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.

    Drug: Conventional Asthma Therapy

Interventions

  • Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily

    Also known as: Pulmicort® Turbuhaler®

  • DrugConventional Asthma Therapy

    According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs).

    AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.

    Time frame: 54 weeks

Secondary outcomes

  1. Number of Patients With Abnormal Clinical Laboratory Test Values.

    Analysis of haematological, clinical chemistry and urynalysis variables were performed. Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count. Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen. Urinalysis variables: protein, glucose, urobilinogen, occult.

    Time frame: 54 weeks

  2. Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator

    Time frame: 54 weeks

  3. Number of Patients With Abnormal Plasma Cortisol Values.

    Cut-off value of cortisol is defined as 4 mcg/dL.

    Time frame: 54 weeks

  4. Height

    Height, change from baseline calculated as (height at last visit - height at randomization)

    Time frame: Baseline and 54 weeks

  5. Weight

    Weight, change from baseline calculated as (weight at last visit - weight at randomization)

    Time frame: Baseline and 54 weeks

  6. Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal

    Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).

    Time frame: 54 weeks

  7. Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)

    Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency

    Time frame: Baseline and 54 weeks

  8. Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)

    Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization). Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.

    Time frame: Baseline and 54 weeks

  9. Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)

    Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)

    Time frame: Baseline and 54 weeks

  10. Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)

    Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)

    Time frame: Baseline and 54 weeks

  11. Change From Baseline in Disturbance of Daily Activities

    Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization). Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).

    Time frame: Baseline and 54 weeks

  12. Change From Baseline in Disturbance of Night-time Sleep

    Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization). Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).

    Time frame: Baseline and 54 weeks

  13. Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline

    Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 \* (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).

    Time frame: 54 weeks

07

Results

Posted Aug 27, 2012

Participant flow

241 Japanese paediatric patients were enrolled into the study

Participant flow — Overall Study
MilestoneBudesonideConventional Therapy
Started121120
Completed109113
Not completed127
Withdrew: Adverse event20
Withdrew: Withdrawal by subject43
Withdrew: Lost to follow-up01
Withdrew: Protocol violation42
Withdrew: Non-compliance21

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs).

AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.

Time frame:
54 weeks
Reported as:
Number · Participants
Number of Patients With Adverse Events (AEs).
ParticipantsBudesonideConventional Therapy
Number of Patients With Adverse Events (AEs).118116
SecondaryNumber of Patients With Abnormal Clinical Laboratory Test Values.

Analysis of haematological, clinical chemistry and urynalysis variables were performed. Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count. Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen. Urinalysis variables: protein, glucose, urobilinogen, occult.

Time frame:
54 weeks
Reported as:
Number · Participants
Number of Patients With Abnormal Clinical Laboratory Test Values.
ParticipantsBudesonideConventional Therapy
Number of Patients With Abnormal Clinical Laboratory Test Values.00
SecondaryNumber of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator
Time frame:
54 weeks
Reported as:
Number · Participants
Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator
ParticipantsBudesonideConventional Therapy
Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator00
SecondaryNumber of Patients With Abnormal Plasma Cortisol Values.

Cut-off value of cortisol is defined as 4 mcg/dL.

Time frame:
54 weeks
Reported as:
Number · Participants
Number of Patients With Abnormal Plasma Cortisol Values.
ParticipantsBudesonideConventional Therapy
Number of Patients With Abnormal Plasma Cortisol Values.2012
SecondaryHeight

Height, change from baseline calculated as (height at last visit - height at randomization)

Time frame:
Baseline and 54 weeks
Reported as:
Mean · Centimeters
Height
CentimetersBudesonideConventional Therapy
Height5.34 ± 1.996.35 ± 1.89
SecondaryWeight

Weight, change from baseline calculated as (weight at last visit - weight at randomization)

Time frame:
Baseline and 54 weeks
Reported as:
Mean · kilograms
Weight
kilogramsBudesonideConventional Therapy
Weight3.78 ± 2.774.39 ± 3.22
SecondaryMorning Peak Expiratory Flow (PEF) Percentage of Predicted Normal

Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).

Time frame:
54 weeks
Reported as:
Mean · Percentage
Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal
PercentageBudesonideConventional Therapy
Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal9.54 ± 19.875.84 ± 17.81
SecondaryChange From Baseline of Respiratory Condition at Asthma Attacks (Daytime)

Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency

Time frame:
Baseline and 54 weeks
Reported as:
Mean · Points on a scale
Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)
Points on a scaleBudesonideConventional Therapy
Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)-0.139 ± 0.334-0.156 ± 0.302
SecondaryChange From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)

Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization). Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.

Time frame:
Baseline and 54 weeks
Reported as:
Mean · Points on a scale
Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)
Points on a scaleBudesonideConventional Therapy
Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)-0.12 ± 0.29-0.147 ± 0.3
SecondaryChange From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)

Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)

Time frame:
Baseline and 54 weeks
Reported as:
Mean · Puffs per day
Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)
Puffs per dayBudesonideConventional Therapy
Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)-0.21 ± 0.647-0.242 ± 0.485
SecondaryChange From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)

Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)

Time frame:
Baseline and 54 weeks
Reported as:
Mean · Puffs per day
Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)
Puffs per dayBudesonideConventional Therapy
Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)-0.07 ± 0.415-0.097 ± 0.368
SecondaryChange From Baseline in Disturbance of Daily Activities

Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization). Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).

Time frame:
Baseline and 54 weeks
Reported as:
Mean · Disturbances per day
Change From Baseline in Disturbance of Daily Activities
Disturbances per dayBudesonideConventional Therapy
Change From Baseline in Disturbance of Daily Activities-0.037 ± 0.141-0.017 ± 0.141
SecondaryChange From Baseline in Disturbance of Night-time Sleep

Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization). Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).

Time frame:
Baseline and 54 weeks
Reported as:
Mean · Disturbances per night
Change From Baseline in Disturbance of Night-time Sleep
Disturbances per nightBudesonideConventional Therapy
Change From Baseline in Disturbance of Night-time Sleep-0.029 ± 0.134-0.042 ± 0.132
SecondaryForced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline

Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 \* (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).

Time frame:
54 weeks
Reported as:
Mean · Percentage
Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline
PercentageBudesonideConventional Therapy
Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline1.5 ± 15.592.31 ± 16.63

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Budesonide—10/121 (8.3%)100/121 (82.6%)
Conventional Therapy—11/120 (9.2%)113/120 (94.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventBudesonideConventional Therapy
AsthmaRespiratory, thoracic and mediastinal disorders5/1216/120
BronchitisRespiratory, thoracic and mediastinal disorders0/1213/120
PneumoniaInfections and infestations1/1212/120
Abdominal painGastrointestinal disorders0/1211/120
Gastroenteritis rotavirusInfections and infestations0/1211/120
HypotensionVascular disorders0/1211/120
Adenoviral conjunctivitisInfections and infestations1/1210/120
AppendicitisInfections and infestations1/1210/120
GastroenteritisInfections and infestations1/1210/120
InfluenzaInfections and infestations1/1210/120
Most frequent other events
Showing 10 of 20
Most frequent other events
EventBudesonideConventional Therapy
Upper Respiratory Tract InfectionInfections and infestations68/12160/120
BronchitisInfections and infestations40/12146/120
PharyngitisInfections and infestations36/12140/120
GastroenteritisInfections and infestations28/12130/120
InfluenzaInfections and infestations30/12127/120
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders26/12122/120
NasopharyngitisInfections and infestations23/12121/120
Conjunctivitis AllergicEye disorders15/12120/120
EczemaSkin and subcutaneous tissue disorders11/12116/120
Otitis MediaInfections and infestations15/12115/120

Baseline characteristics

Age Continuous
Age Continuous(Years)BudesonideConventional TherapyTotal
Mean8.9 ± 2.68.6 ± 2.38.8 ± 2.5
Sex: Female, Male
Sex: Female, Male(Participants)BudesonideConventional TherapyTotal
Female362763
Male8593178
08

Study locations

1 site
  • Research Site
    Takizawa, Iwate, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2007
First posted
Jul 31, 2007
Start
Dec 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Aug 27, 2012
Last update
Aug 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00509028
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 31, 2007
Start date
Dec 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Aug 27, 2012
Last update
Aug 27, 2012

Study contacts

Lars-Goran Carlsson, MD
study director · AstraZeneca R&D Lund

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion